| Literature DB >> 36074783 |
Pratiwi Soedarmono1, Aly Diana2,3, Patricia Tauran4, Dewi Lokida5, Abu Tholib Aman6, Bachti Alisjahbana7, Dona Arlinda8, Emiliana Tjitra8, Herman Kosasih2, Ketut Tuti Parwati Merati9, Mansyur Arif4, Muhammad Hussein Gasem10, Nugroho Harry Susanto2, Nurhayati Lukman2, Retna Indah Sugiyono2, Usman Hadi11, Vivi Lisdawati12, Karine G Fouth Tchos13, Aaron Neal13, Muhammad Karyana2,8.
Abstract
Blood culturing remains the "gold standard" for bloodstream infection (BSI) diagnosis, but the method is inaccessible to many developing countries due to high costs and insufficient resources. To better understand the utility of blood cultures among patients in Indonesia, a country where blood cultures are not routinely performed, we evaluated data from a previous cohort study that included blood cultures for all participants. An acute febrile illness study was conducted from July 2013 to June 2016 at eight major hospitals in seven provincial capitals in Indonesia. All participants presented with a fever, and two-sided aerobic blood cultures were performed within 48 hours of hospital admission. Positive cultures were further assessed for antimicrobial resistance (AMR) patterns. Specimens from participants with negative culture results were screened by advanced molecular and serological methods for evidence of causal pathogens. Blood cultures were performed for 1,459 of 1,464 participants, and the 70.6% (1,030) participants that were negative by dengue NS1 antigen test were included in further analysis. Bacteremia was observed in 8.9% (92) participants, with the most frequent pathogens being Salmonella enterica serovar Typhi (41) and Paratyphi A (10), Escherichia coli (14), and Staphylococcus aureus (10). Two S. Paratyphi A cases had evidence of AMR, and several E. coli cases were multidrug resistant (42.9%, 6/14) or monoresistant (14.3%, 2/14). Culture contamination was observed in 3.6% (37) cases. Molecular and serological assays identified etiological agents in participants having negative cultures, with 23.1% to 90% of cases being missed by blood cultures. Blood cultures are a valuable diagnostic tool for hospitalized patients presenting with fever. In Indonesia, pre-screening patients for the most common viral infections, such as dengue, influenza, and chikungunya viruses, would maximize the benefit to the patient while also conserving resources. Blood cultures should also be supplemented with advanced laboratory tests when available.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36074783 PMCID: PMC9455855 DOI: 10.1371/journal.pone.0273414
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1General blood culture results observed among study participants.
Participants provided blood from either one or both arms for aerobic blood cultures, and bacterial growth was observed from either one or both sides. All participants providing blood underwent screening for dengue virus infection by NS1 antigen test.
Specific blood culture results among dengue-negative study participants.
| Pathogen | Positive Results | Percent of Positive Results Within Group | |
|---|---|---|---|
| WHO GLASS Priority Pathogens (N = 84) | 51 | 60.7 | |
|
| 14 | 16.7 | |
|
| 10 | 11.9 | |
|
| 5 | 6.0 | |
| 2 | 2.4 | ||
|
| 2 | 2.4 | |
| Non-WHO GLASS Pathogens (N = 8) |
| 2 | 25.0 |
| 1 | 12.5 | ||
|
| 1 | 12.5 | |
|
| 1 | 12.5 | |
|
| 1 | 12.5 | |
| 1 | 12.5 | ||
|
| 1 | 12.5 | |
| Clinically Irrelevant Growth (N = 7) | 2 | 28.6 | |
|
| 2 | 28.6 | |
|
| 1 | 14.3 | |
|
| 1 | 14.3 | |
|
| 1 | 14.3 | |
| Contaminants (N = 37) |
| 32 | 86.5 |
| 2 | 5.4 | ||
|
| 1 | 2.7 | |
| 1 | 2.7 | ||
|
| 1 | 2.7 | |
| No Growth (N = 894) |
| 0 | 0.0 |
Participant characteristics, hematology results, and mortality.
| True Positive (92) | False Positive and No Growth (938) | Total (1,030) | ||
|---|---|---|---|---|
| Non- | ||||
| Male, N (%) | 29 (56.9) | 17 (41.5) | 502 (53.9) | 553 (53.7) |
| Median age, years (range, IQR) | 14 (2.5–54, 14.7) | 44 (1–84, 40.0) | 24.6 (1–92, 36.5) | 24 (1–92, 36.2) |
| Mean age, years (SD) | 16.2 (11.1) | 39.6 (24.0) | 28.6 (21.4) | 28.5 (21.4) |
| Distribution of cases by age group, N (%) | ||||
| 1–5 years | 4 (7.8) | 5 (12.2) | 154 (16.4) | 163 (15.8) |
| >5–18 years | 28 (54.9) | 6 (14.6) | 184 (19.6) | 218 (21.2) |
| >18–45 years | 18 (35.3) | 11 (26.8) | 365 (38.9) | 394 (38.3) |
| >45–65 years | 1 (2.0) | 13 (31.7) | 179 (19.1) | 193 (18.7) |
| >65 years | 0 (0.0) | 6 (14.6) | 56 (6.0) | 62 (6.0) |
| Days of onset before hospitalization, median (range, IQR) | 7 (1–13, 4) | 4 (1–15, 4) | 4 (1–15, 4) | 4 (1–15, 4) |
| Length of hospitalization, median (range, IQR) | 7 (2–38, 4) | 8 (2–40, 7) | 6 (1–55, 3.3) | 6 (1–55, 4) |
| Received intravenous antibiotics prior to blood collection, N (%) | 9 (17.6) | 16 (39.0) | 389 (41.5) | 414 (40.2) |
| Received any antibiotics following blood collection, N (%) | 31/31 (100) | 18/18 (100) | 199/269 (74.0) | 248/318 (77.9) |
| Hematology at enrollment, N (%) | ||||
| Leukopenia | 13/51 (25.5) | 5/41 (12.2) | 120/937 (12.8) | 138/1029 (13.4) |
| Normal Leukocyte | 35/51 (68.6) | 19/41 (46.3) | 462/937 (49.3) | 516/1029 (50.1) |
| Leukocytosis | 3/51 (5.9) | 17/41 (41.5) | 355/937 (37.9) | 375/1029 (36.4) |
| Lymphopenia | 16/44 (36.4) | 26/38 (68.4) | 442/810 (54.6) | 484/892 (54.3) |
| Normal Lymphocyte | 17/44 (38.6) | 7/38 (18.4) | 285/810 (35.2) | 309/892 (34.6) |
| Lymphocytosis | 11/44 (25.0) | 5/38 (13.2) | 83/810 (10.2) | 99/892 (11.1) |
| Outcome, N (%) | ||||
| Died | 3 (5.9) | 11 (26.8) | 69 (7.4) | 83 (8.1) |
Study participants with true positive culture results were sub-categorized into Salmonella spp. (consisted of Salmonella enterica serovar Typhi and Paratyphi A) and non-Salmonella spp. groups to better resolve analyses. Comparisons for significance occur across column groups only.
A,B,C indicates p-value <0.05
D,E,F indicates p-value <0.01
Positive blood culture pathogens by participant age group and study location.
| Pathogen Identified | Age group (years old) | Location | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥1–5 | >5–18 | >18–45 | >45–65 | >65 | Bdg | Sby | Smr | Dps | Mks | Yog | Jkt | ||
| 4 | 28 (1 | 18 (1 | 1 (1 | 0 | 21 | 11 | 12 | 1 | 5 | 1 | 0 | 51 | |
|
| 1 | 1 | 3 (1 | 5 (1 | 4 | 3 | 3 | 0 | 4 | 0 | 3 | 1 | 14 |
|
| 0 | 2 | 4 (1 | 4 (1 | 0 | 1 | 1 | 3 | 2 | 1 | 0 | 2 | 10 |
|
| 0 | 1 | 0 | 3 (2 | 1 | 0 | 1 | 0 | 2 | 2 | 0 | 0 | 5 |
| 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 | |
|
| 0 | 0 | 1 (1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
|
| 1 | 0 | 1 (1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
|
| 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
|
| 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
|
| 1 (1 | 1 (1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 2 |
|
| 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
|
| 1 (1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
|
| 9 (2 | 34 (2 | 29 (5 | 14 (5 | 6 | 27 | 17 | 15 | 12 | 9 | 7 | 5 | 92 |
† Indicates study participants who died
Bdg: Bandung; Sby: Surabaya; Smr: Semarang; Dps: Denpasar; Mks: Makassar; Yog: Yogyakarta; Jkt: Jakarta
Pathogens detected by molecular, serological, or other laboratory methods from participants with false positive and no growth blood cultures.
| False Positive and No Growth (N = 938) | Confirmatory Methods | |||
|---|---|---|---|---|
| Pathogen | N | Blood PCR | Serology | Other Methods |
|
| 101 | 65 | 36 | |
| Influenza | 66 | 0 | 59 | 7: Sputum PCR |
| 51 | 3 | 48 | ||
| 44 | 31 | 13 | ||
| Chikungunya | 38 | 30 | 8 | |
| Dengue | 35 | 0 | 35 | |
|
| 20 | 0 | 0 | 20: Sputum Microscopy |
|
| 18 | 10 | 0 | 8: Sputum PCR |
| Measles | 14 | 9 | 5 | |
| Amoeba | 11 | 0 | 0 | 11: Feces Microscopy |
| RSV | 11 | 0 | 9 | 2: Swab PCR |
| HHV-6 | 9 | 9 | 0 | |
|
| 8 | 1 | 0 | 5: Sputum Culture |
|
| 7 | 1 | 0 | 4: Sputum PCR |
|
| 7 | 1 | 0 | 4: Urine Culture |
| Hepatitis A | 6 | 0 | 6 | |
|
| 6 | 0 | 0 | 4: Sputum Culture |
|
| 3 | 0 | 0 | 2: Pus Culture |
|
| 3 | 0 | 0 | 3: Pus Culture |
|
| 2 | 0 | 0 | 2: Skin Microscopy |
| 2 | 0 | 0 | 2: Rapid Antigen Test | |
| Seoul virus | 2 | 2 | 0 | |
| Adenovirus | 1 | 1 | 0 | |
|
| 1 | 0 | 0 | 1: Feces Microscopy |
| 1 | 0 | 0 | 1: Feces Microscopy | |
| 1 | 0 | 0 | 1: Sputum PCR | |
| HCoV-OC43 | 1 | 1 | 0 | |
|
| 1 | 0 | 0 | 1: Sputum Culture |
|
| 1 | 0 | 0 | 1: Sputum Culture and PCR |
|
| 1 | 0 | 0 | 1: Pus Culture |
| Enterovirus | 1 | 1 | 0 | |
| EPEC | 1 | 0 | 0 | 1: Feces Culture |
| HIV | 1 | 1 | 0 | |
| Metapneumovirus | 1 | 0 | 0 | 1: Swab PCR |
| 1 | 0 | 0 | 1: Sputum Culture and PCR | |
|
| 1 | 0 | 0 | 1: Sputum PCR |
| Norovirus II | 1 | 1 | 0 | |
|
| 1 | 1 | 0 | |
| Rubella | 1 | 0 | 1 | |
|
| 1 | 0 | 0 | 1: Urine Culture |
| Unknown | 456 | 0 | 0 | |
|
|
|
|
|
|
Plasma, serum, and clinically relevant specimens were collected from all study participants and tested in a central lab for culturable and non-culturable pathogens based on a standard study algorithm and clinical suspicion.
Fig 2Antimicrobial resistance patterns observed in WHO GLASS priority pathogens from true positive blood cultures.
Participants with resistant (R) infections are identified by study location, and participants with sensitive (S) infections or infections with no testing data (ND) are grouped into Other or No Data categories.
Participant characteristics, clinical diagnoses, and identified pathogens from fatal cases in the study.
| (A) Characteristics of deceased participants categorized by blood culture growth result. | ||||
|
|
|
| ||
|
|
| |||
| Male, N (%) | 3 (100) | 7 (63.6) | 36 (52.2) | 46 (55.4) |
| Distribution of cases by age group, N (%) | ||||
| 1–5 years | 0 (0.0) | 2 (18.2) | 4 (5.8) | 6 (7.2) |
| >5–18 years | 1 (33.3) | 1 (9.1) | 7 (10.1) | 9 (10.8) |
| >18–45 years | 1 (33.3) | 4 (36.4) | 24 (34.8) | 29 (34.9) |
| >45–65 years | 1 (33.3) | 4 (36.4) | 25 (36.2) | 30 (36.1) |
| >65 years | 0 (0.0) | 0 (0.0) | 9 (13) | 9 (10.8) |
| Received intravenous antibiotics prior to blood collection, N (%) | 1 (33.3) | 1 (9.1) | 34 (49.3) | 36 (43.4) |
| Length of hospitalization, median (range, IQR) | 4 (2–38) | 12 (2–17) | 8 (2–54) | 8 (2–54) |
| Comorbidities, N (%) | 2 (66.6) | 10 (90.9) | 60 (86.9) | 72 (86.7) |
| (B) Pathogens from fatal cases confirmed by blood culture or other lab methods and the accompanying clinical diagnoses, participant comorbidities, and AMR observations | ||||
|
|
|
|
| |
| Typhoid fever | Hepatitis B, HIV, TB | None | ||
| Acute limb ischemia | Acute Limb Ischemia | None | ||
| Sepsis, typhoid fever | Transfusion-Related Acute Lung Injury (TRALI) | None | ||
| Cholangitis | Diabetes, Hepatitis B | Yes | ||
| Sepsis | Anemia | Yes | ||
| UTI, diabetic ketoacidosis | Diabetes | None | ||
| UTI | Stroke | None | ||
| UTI | Diabetes | None | ||
| Sepsis | Diabetes, Chronic Kidney Disease | None | ||
| Aseptic meningitis, acute otitis media | Epilepsy | Yes | ||
| Myelodysplasia, Hepatitis B (Cirrhosis) | None | |||
| Stevens-Johnson syndrome | HIV, TB, Toxoplasmosis | No data | ||
| Cholangitis, Sepsis | None | No data | ||
| Craniopharyngioma | None | |||
|
|
| |||
| Pulmonary TB (3), Colitis TB and Spondylitis TB, Millar TB, HIV, Community-acquired Pneumonia, Sepsis | ||||
| Sepsis (3), Community-acquired Pneumonia, Meningoencephalitis, Diabetic Neuropathy | ||||
| Influenza (3) [PCR (2), Serology (1)] | Bronchiectasis, Community-acquired Pneumonia, Sepsis | |||
| Hirschsprung’s disease, HIV | ||||
| Community-acquired Pneumonia | ||||
| Typhoid Fever | ||||
| Diabetic Ulcer | ||||
| UTI | ||||
| HIV (1) [PCR] | Sepsis | |||
| Dengue Hemorrhagic Fever I | ||||
| Community-acquired Pneumonia | ||||
| RSV (1) [Serology] | TB Pleuritis | |||
| Community-acquired Pneumonia | ||||
| Unknown (41) [None] | HIV (6), Sepsis (6), Community-acquired Pneumonia (9), Cellulitis (2), Cholangitis (2), Lung Abscess, Acute Leukemia, Bacterial Meningitis, Bronchitis, Cholecystitis, Chronic Myelocytic Leukemia, COPD, Diarrhea, Extrapulmonary TB, GEA, Hepatitis B, Pancytopenia, SLE, Typhoid Fever, UTI, Unknown | |||